01 December 2009
Growth factors enhance endothelial progenitor cell proliferation under high-glucose conditions
Wei LiABCDEF, Shiyu Y. YangACD, Zhong F. HuCF, Marc C. WinsletAD, Wen WangF, Alexander M. SeifalianACDEFGMed Sci Monit 2009; 15(12): BR357-363 :: ID: 878271
Abstract
Background
The purpose of this study was to investigate the impact of growth regulators, including growth hormone (GH), insulin-like growth factor 1 (IGF-1), and mechano growth factor (MGF), on endothelial progenitor cell (EPC) proliferation at different glucose concentrations.
Material and Method
EPCs were isolated and cultured from peripheral blood samples of healthy volunteers and immunocytochemically characterized after 7 days. The effects of glucose and growth regulators on EPC proliferation were determined with the Alamar Blue and Trypan Blue assays. The effect of glucose supplementation at 2.5, 11.1, and 25.0 mM was examined using cells seeded at densities of 15000, 30000, and 45000 cells/ml.
Results
For the GH-treated cells, enhancement of EPC proliferation was detected in the samples supplemented with 11.1 and 25.0 mM glucose. A slight elevation in EPC proliferation was only observed in the IGF-1-treated cells supplemented with 25.0 mM glucose. Significant enhancement of EPC proliferation was observed in MGF-treated cells supplemented with 11.1 and 25.0 mM glucose. All three growth factors demonstrated enhancement of cellular proliferation when the cells were supplemented with 25.0 mM glucose. No enhancement of EPC proliferation by the growth factors was detected in any of the cells supplemented with 2.5 mM glucose.
Conclusions
GH, IGF-1, and MGF enhance EPC proliferation under 25.0 mM glucose conditions. The presence of these growth regulators in EPC culture may contribute to protecting EPCs from high-glucose conditions. This action may be of therapeutic relevance contributing to beneficial cardiovascular effects for diabetic patient.
Keywords: Human Growth Hormone - pharmacology, Growth Substances - pharmacology, Glucose - pharmacology, Endothelial Cells - metabolism, Cell Proliferation - drug effects, Adult Stem Cells - metabolism, Insulin-Like Growth Factor I - pharmacology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952